<DOC>
	<DOC>NCT01710644</DOC>
	<brief_summary>The purpose of this Randomized, Double-blind, Multicenter, Two-period Crossover Study is to Assess the Efficacy and Tolerability of Burlulipase (NM-BL) in Patients with Exocrine Pancreatic Insufficiency due to Cystic Fibrosis</brief_summary>
	<brief_title>Efficacy and Tolerability of NM-BL in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Respiratory Tract Diseases</mesh_term>
	<mesh_term>Exocrine Pancreatic Insufficiency</mesh_term>
	<mesh_term>Digestive System Diseases</mesh_term>
	<mesh_term>Gastrointestinal Diseases</mesh_term>
	<criteria>Male and female patients aged ≥12 years from the date of informed consent Confirmed diagnosis of CF at screening Confirmed EPI by historical (within past 12 months) CFA &lt;70% without use of PERTs or current fecal elastase &lt;50 µg/g stool at screening Currently receiving PERT with a commercially available pancreatic enzyme Currently on stable treatment with proton pump inhibitors or H2 receptor antagonists Clinically stable condition without evidence of acute respiratory disease or any other acute condition History of fibrosing colonopathy History of significant bowel resection, in the opinion of the investigator, or solid organ transplant History of being refractory to pancreatic enzyme replacement Current diagnosis or history of distal intestinal obstruction syndrome Current diagnosis of small intestinal bacterial overgrowth, ileus or acute abdomen A body mass index percentile &lt;10%</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>